 Amortization expense for intangible assets was $7.8 million and $5.5 million, respectively, during the three months ended December 31, 2018 and 2017.
The acquisition of Tec-Sem has expanded the Company’s contamination control solutions business within the Brooks Semiconductor Solutions Group segment.
The revenues and net income from Tec-Sem included in the Company's consolidated results for the three months ended December 31, 2018 were $9.3 million and $1.7 million, respectively.
During the three months ended December 31, 2017, the net loss also included non-recurring charges of $1.2 million related to the step-up in value of the acquired inventories.
There were no transaction costs related to the 4titude acquisition during the three months ended December 31, 2018.
During the three months ended December 31, 2018, revenue and net income from 4titude recognized in the Company’s results of operations were $3.9 million and less than $0.1 million, respectively.
  The Company recorded an income tax benefit of $5.8 million and $0.7 million, respectively, for the three months ended December 31, 2018 and the three months ended December 31, 2017.
Pro forma revenue for the three months ended December 31, 2018 has been decreased by $0.4 million for the adoption of ASC 606.
The acquisition of 4titude will expand the Company’s existing offerings of consumables and instruments within the Brooks Life Sciences segment.
We have aggregated the two operating segments as one reporting segment based on similarities in long-term forecasted economic characteristics, particularly adjusted operating income, similarity in services they offer, the customers they serve, the nature of their service delivery models, and their regulatory environments.
 In the fourth quarter of fiscal year 2018, the Company entered into a definitive agreement to sell its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group), (the “Disposition”).
The support services include repair services, diagnostic support services, and installation services in support of the products, which enable the customers to maximize process tool uptime and productivity.We had no customers that accounted for 10% or more of our consolidated revenue for each of the three months ended December 31, 2018 and 2017.
Operating income was $5.3 million during the first quarter of fiscal year 2018 as compared to $4.9 million for the corresponding period of the prior fiscal year.
Gross margin was 40.2% for the three months ended December 31, 2018 as compared to 38.1% for the corresponding period of the prior fiscal year, which resulted in an increase in gross profit of $17.8 million in the first quarter of fiscal year 2019 as compared to the corresponding period of the fiscal year 2018.
 Research and development expenses were $13.1 million during the three months ended December 31, 2018 as compared to $11.4 million during the corresponding period of the prior fiscal year.
The increase in interest expense is due to interest on the $350.0 million incremental term loan secured in the first quarter of fiscal year 2019 used to pay a portion of the purchase price for our acquisition of GENEWIZ.
Gross margin increased in the Brooks Semiconductor Solutions Group segment by 0.3 percentage points and in the Brooks Life Sciences segment by 6.0 percentage points in the 2019 period over the 2018 period.